Showing results (141-150 of 355) with videos related to

Sort By:
Pageof 36
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
JACC. Heart Failure|July 13, 2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF TrialScott D Solomon, Pardeep S Jhund, Brian L Claggett, et al.
Transplantation|February 25, 2016
B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant RecipientsPetr Jarolim, Brian L Claggett, Michael J Conrad, et al.
Journal of the American Heart Association|September 23, 2020
NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes MellitusMarcus V B Malachias, Pardeep S Jhund, Brian L Claggett, et al.
Circulation. Heart Failure|May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
European Journal of Heart Failure|November 17, 2022
Health-related quality of life outcomes in PARAGON-HFAlvin Chandra, Carisi A Polanczyk, Brian L Claggett, et al.
Circulation. Heart Failure|March 1, 2024
Metabolomic Association and Risk Prediction With Heart Failure in Older AdultsGuning Liu, Ngoc Quynh H Nguyen, Kari E Wong, et al.
European Journal of Heart Failure|June 27, 2024
Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HFMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
European Journal of Heart Failure|April 10, 2026
Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HFIris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
European Journal of Heart Failure|May 14, 2024
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trialMuthiah Vaduganathan, Brian L Claggett, Carolyn S P Lam, et al.
Pageof 36